Espín Armas, Estefanía Alejandra(Universitat Politècnica de València, 2015-05-11)
[EN] HER2-overexpressing breast cancer has an aggressive phenotype and poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has demonstrated therapeutic efficacy on this breast cancer subtype. Nonetheless, primary ...